Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1635 1636 1674
This examiner grants 72% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18272933 | ENGINEERED NUCLEIC ACIDS TARGETING LONG NONCODING RNA INVOLVED IN PATHOGENIC INFECTION | Non-Final OA | President and Fellows of Harvard College |
| 18021469 | CRISPR-CAS EFFECTOR POLYPEPTIDES AND METHODS OF USE THEREOF | Non-Final OA | The Regents of the University of California |
| 17930180 | HSD17B13 VARIANTS AND USES THEREOF | Final Rejection | Regeneron Pharmaceuticals, Inc. |
| 18069387 | ENGINEERED NUCLEASES AND METHODS OF USE THEREOF | Final Rejection | Massachusetts Institute of Technology |
| 18314661 | CELL SPECIFIC GENE THERAPY DELIVERY COMPOSITIONS AND METHODS FOR TREATING HEARING LOSS | Non-Final OA | Akouos, Inc. |
| 16954171 | CRISPR-MEDIATED GENOME EDITING WITH VECTORS | Final Rejection | Regents of the University of Minnesota |
| 17782976 | EXOSOMES-BASED THERAPY FOR LIVER FIBROSIS AND OTHER DISEASES WITH FIBROSIS | Non-Final OA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 17837325 | PLANT VIRAL NUCLEIC ACID DELIVERY PARTICLES AND USES THEREOF | Non-Final OA | CASE WESTERN RESERVE UNIVERSITY |
| 18019720 | Human XIST Antisense Oligonucleotides for X Reactivation Therapy | Non-Final OA | The General Hospital Corporation |
| 17920342 | COMPOSITIONS AND METHODS FOR INTRANASAL TREATMENT WITH DOUBLE STRANDED RNA | Final Rejection | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK |
| 17642986 | METHODS FOR DEPLETION OF DELETERIOUS MITOCHONDRIAL GENOMES | Non-Final OA | University of Massachusetts |
| 18301089 | PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | Non-Final OA | Alnylam Pharmaceuticals, Inc. |
| 17639263 | VASCULOGENIC FIBROBLASTS | Non-Final OA | THE TRUSTEES OF INDIANA UNIVERSITY |
| 17754844 | MODULATORS OF PNPLA3 EXPRESSION | Non-Final OA | AstraZeneca AB |
| 18148466 | METHOD OF TREATING BREAST CANCER IN A SUBJECT BY INHIBITING TUBB2B | Non-Final OA | City University of Hong Kong |
| 18054660 | SINGLE-STRANDED OLIGONUCLEOTIDE | Non-Final OA | NISSAN CHEMICAL CORPORATION |
| 18176396 | STING-DEPENDENT ACTIVATORS FOR TREATMENT OF DISEASE | Non-Final OA | University of Miami |
| 17700066 | COMPOSITIONS AND METHODS FOR DETECTING AND TREATING INSULIN RESISTANCE | Non-Final OA | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO |
| 18546462 | COMPOUNDS AND METHODS FOR REDUCING NLRP3 EXPRESSION | Non-Final OA | IONIS PHARMACEUTICALS, INC. |
| 17306860 | ENZYMATIC REPLACEMENT THERAPY AND ANTISENSE THERAPY FOR POMPE DISEASE | Non-Final OA | Erasmus University Medical Center Rotterdam |
| 18059213 | SYSTEMS AND METHODS FOR TREATING ALPHA 1-ANTITRYPSIN (A1AT) DEFICIENCY | Non-Final OA | EDITAS MEDICINE, INC. |
| 18449861 | Deuterium-Stabilised Ribonucleic Acid (RNA) Molecules Displaying Increased Resistance to Thermal and Enzymatic Hydrolysis, Aqueous Compositions Comprising Stabilised RNA Molecules and Methods for Making Same | Non-Final OA | deutraMed Solutions Ltd. |
| 17935297 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Non-Final OA | Design Therapeutics, Inc. |
| 17046465 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Non-Final OA | Design Therapeutics, Inc. |
| 18267015 | COMPLEX FOR TREATING OPTIC NERVE DISEASE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Non-Final OA | CHENGDU GENREZE GENE TECHNOLOGY CO., LTD. |
| 17905442 | PREVENTION OR TREATMENT OF ANEURYSMS USING MIR-33B INHIBITOR | Non-Final OA | NATIONAL INSTITUTES OF BIOMEDICAL INNOVATION, HEALTH AND NUTRITION |
| 17638723 | MOLECULAR TARGETED NUCLEIC ACID MEDICINE FOR GASTRIC CANCER | Final Rejection | National Institutes of Biomedical Innovation, Health and Nutrition |
| 18033748 | OLIGONUCLEOTIDES USEFUL FOR MODULATION OF SPLICING | Non-Final OA | REMIX THERAPEUTICS INC. |
| 18302580 | ANTISENSE OLIGONUCLEOTIDES AND USES THEREOF | Final Rejection | FUNDACIÓN DEL SECTOR PÚBLICO ESTATAL CENTRO NACIONAL DE INVESTIGACIONES ONCO |
| 17817781 | CRISPR-CAS9 MEDIATED DISRUPTION OF ALCAM GENE INHIBITS ADHESION AND TRANS-ENDOTHELIAL MIGRATION OF MYELOID CELLS | Final Rejection | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy